60 Degrees Pharmaceuticals Inc. (NASDAQ:SXTP) Short Interest Down 49.0% in February

60 Degrees Pharmaceuticals Inc. (NASDAQ:SXTP) was the recipient of a significant drop in short interest in February. As of February 13th, there was short interest totaling 107,275 shares, a drop of 49.0% from the January 29th total of 210,488 shares. Based on an average daily trading volume, of 404,658 shares, the days-to-cover ratio is presently 0.3 days. Approximately 10.3% of the company’s shares are short sold. Approximately 10.3% of the company’s shares are short sold. Based on an average daily trading volume, of 404,658 shares, the days-to-cover ratio is presently 0.3 days.

60 Degrees Pharmaceuticals Stock Performance

SXTP traded up $0.15 on Friday, hitting $3.11. 31,977 shares of the company were exchanged, compared to its average volume of 242,966. 60 Degrees Pharmaceuticals has a fifty-two week low of $1.36 and a fifty-two week high of $17.68. The firm has a market capitalization of $3.29 million, a P/E ratio of -0.22 and a beta of 2.94. The business’s fifty day moving average is $3.14 and its 200 day moving average is $4.41.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently weighed in on the company. HC Wainwright increased their price target on 60 Degrees Pharmaceuticals from $6.00 to $24.00 and gave the stock a “buy” rating in a report on Tuesday, January 27th. Ascendiant Capital Markets reduced their price objective on 60 Degrees Pharmaceuticals from $12.00 to $11.20 and set a “buy” rating on the stock in a research note on Friday, November 28th. Zacks Research raised shares of 60 Degrees Pharmaceuticals to a “hold” rating in a research report on Tuesday, November 18th. Finally, Weiss Ratings restated a “sell (e+)” rating on shares of 60 Degrees Pharmaceuticals in a research note on Monday, December 29th. Two investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average price target of $17.60.

60 Degrees Pharmaceuticals Company Profile

60 Degrees Pharmaceuticals, Inc, a specialty pharmaceutical company, engages in the development and commercialization of therapies for the prevention and treatment of infectious diseases in the United States. The company offers Arakoda for malaria preventative treatment. It also engages in the development of Tafenoquine (Arakoda regimen) that is in Phase IIb clinical trial for COVID-19 indications; Tafenoquine, which is in phase IIA clinical trials for babesiosis, fungal pneumonias, and candidiasis disease; and Celgosivir for respiratory viruses and dengue.